Only 21% of patients with diabetes, hypertension, or both underwent urine albumin-to-creatinine ratio testing in a year, despite guideline recommendations, a large recent study found.
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which was funded by Novo Nordisk and the National Institutes of Health, randomized 9,340 patients ages 50 years and older to 1.8 mg of
Risk factor control was more strongly associated with mortality risk among patients with cardiorenal disease than those without, according to a retrospective British study.
A small subgroup analysis of two randomized trials found that median time to resolution of diabetic ketoacidosis was 13 hours in patients who received balanced crystalloids versus nearly 17 hours in those who received saline.
In a recent study, a serum C-peptide testing program resulted in reclassification of the cause of diabetes in about 7% of the cohort tested at one diabetes center in Scotland. Reclassification was most likely in those diagnosed at age 30 years or
The American Diabetes Association (ADA) 2021 Standards of Medical Care in Diabetes now reflect new data on teplizumab and sodium-glucose cotransporter-2 inhibitors, as well as the effects of dapagliflozin and finerenone on patients with chronic
A pooled analysis of three randomized clinical trials found reductions in major adverse cardiac or cerebrovascular events after percutaneous coronary intervention (PCI) at 3.9-year follow-up only in patients with low-density lipoprotein (LDL)
The authors of a systematic review and meta-analysis recommended reconsideration of guidelines on sodium-glucose cotransporter-2 (SGLT-2) inhibitors to increase use among patients at risk of cardiovascular disease.
Metformin appears to be associated with reduced mortality at estimated glomerular filtration rates as low as 45 mL/min/1.73 m2, but safety concerns arise with rates at or below 30 mL/min/1.73 m2.
The advent of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists could reduce cardiovascular adverse events and progression to end-stage kidney disease, the American Heart Association (AHA) scientific statement